Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Accolade, Inc. (NASDAQ: ACCD) announces a significant change in its Board of Directors as Co-founder Michael Hilton transitions from his role as Chief Product Officer to joining the Board, succeeding Tom Neff. Hilton has been pivotal in reshaping Accolade's market strategy since 2015, enhancing its position from a service provider to a product leader. CEO Rajeev Singh commended Hilton's experience, while expressing gratitude for Neff's long-standing contributions. The company's approach combines advanced healthcare services with intelligent technology to improve patient experiences, consistently achieving over 90% consumer satisfaction ratings.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal third quarter 2023 revenue of $90.9 million, a 9% increase from $83.5 million in the same quarter last year. However, the company experienced a significant net loss of $39.9 million, compared to a net income of $22.5 million in fiscal Q3 2022, reflecting a 277% decline. Adjusted EBITDA improved by 14% to $(10.2 million, while adjusted gross profit rose 6% to $41.8 million. The company reaffirmed its 2024 revenue growth and Adjusted EBITDA targets, aiming for positive cash flow by fiscal 2025.
Accolade, Inc. (NASDAQ: ACCD) will engage in the 25th Annual Needham Growth Conference on January 11, 2023, hosting a fireside chat at 1:30 pm ET. The event will be accessible via a webcast and replay on their investor relations website. Accolade offers healthcare solutions that enhance the patient experience through personalized, data-driven services. The company boasts a consumer satisfaction rating exceeding 90%, reflecting its commitment to improving healthcare outcomes and lowering costs.
Accolade, Inc. (NASDAQ: ACCD) announced it will release its fiscal third quarter 2023 financial results on January 9, 2023, after market close. The company will host a conference call at 4:30 p.m. E.T. to review the results. Accolade provides healthcare solutions to millions, emphasizing a personalized and value-based approach that includes virtual primary care and expert medical opinions. The company consistently achieves consumer satisfaction ratings above 90%. For more details, visit their website.
Accolade, Inc. (Nasdaq: ACCD) is advocating for equitable healthcare as a Health Equity Impact Champion sponsor at HLTH 2022. The company has welcomed FOLX Health, an LGBTQIA+ affirming care provider, into its Trusted Partner Ecosystem, enhancing its offerings to over 11 million members. Accolade's Chief Medical Officer and Deloitte Managing Director discussed employers' roles in improving healthcare access. The Trusted Partner Ecosystem, now celebrating three years, integrates various health solutions, providing significant value to employers and improving healthcare experiences for marginalized communities.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal Q2 2023 revenue of $87.6 million, marking a 20% increase from $73.3 million in Q2 2022.
The company achieved a net loss of $46.5 million, improved by 25% year-over-year.
Adjusted gross profit grew by 31% to $39.2 million with a margin of 44.7%.
Accolade raised its revenue guidance for fiscal 2023 and anticipates positive cash flow and Adjusted EBITDA in fiscal year 2025.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q2 2023 financial results on October 6, 2022, after market close. A conference call to discuss the results will occur at 4:30 p.m. E.T. on the same day. Accolade provides personalized healthcare solutions, serving over 600 employers and millions of members, combining virtual care, mental health support, and care navigation. The company boasts a consumer satisfaction rating exceeding 90%. For more details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) announced participation in two investor conferences on September 13, 2022. The Morgan Stanley 20th Annual Global Healthcare Conference will occur at 10:35am ET, followed by the Baird’s 2022 Global Healthcare Conference at 10:50am ET. The company focuses on enhancing healthcare experiences through virtual primary care, mental health support, and intelligent care navigation, boasting over 90% consumer satisfaction ratings. Webcasts and replays will be available on their investor relations site.
Summary not available.
Accolade, Inc. (Nasdaq: ACCD) has appointed Kelli Burns as its new senior vice president and chief information security officer as of July 25, 2022. Burns, previously with Ernst & Young and Symetra Financial, brings extensive cybersecurity expertise. She will lead Accolade's information security strategy, enhancing data protection for its over 600 enterprise clients, including major employers and government entities. The move underscores Accolade's commitment to safeguarding customer information as part of its Personalized Healthcare mission.